Bortezomib-induced Sweet's syndrome

Haematologica. 2005 Dec;90(12 Suppl):ECR43.

Abstract

Sweet's syndrome is an uncommon acute skin disease, associated with a variety of medical problems. The drug-induced variant is even rarer. We describe two cases of this syndrome associated with the administration of the proteasome inhibitor bortezomib. The diagnostic criteria for drug-induced Sweet's syndrome as proposed by Walker and Cohen were fulfilled. Vasculitis and neutrophilic eccrine hidradenitis were excluded.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Boronic Acids / administration & dosage
  • Boronic Acids / adverse effects*
  • Bortezomib
  • Drug Administration Schedule
  • Erectile Dysfunction / chemically induced
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Melphalan / administration & dosage
  • Methylprednisolone / therapeutic use
  • Multiple Myeloma / drug therapy
  • Pain / chemically induced
  • Peripheral Nervous System Diseases / chemically induced
  • Prednisolone / administration & dosage
  • Protease Inhibitors / administration & dosage
  • Protease Inhibitors / adverse effects*
  • Pyrazines / administration & dosage
  • Pyrazines / adverse effects*
  • Recurrence
  • Sleep Initiation and Maintenance Disorders / chemically induced
  • Sweet Syndrome / chemically induced*
  • Sweet Syndrome / diagnosis
  • Sweet Syndrome / drug therapy
  • Sweet Syndrome / pathology
  • Testicular Diseases / chemically induced

Substances

  • Boronic Acids
  • Immunosuppressive Agents
  • Protease Inhibitors
  • Pyrazines
  • Bortezomib
  • Prednisolone
  • Melphalan
  • Methylprednisolone